高尿酸血症参与者中痛风诊断的发生率:一项全国性队列研究的发现
这项回顾性全国性以色列队列研究利用Clalit健康保险数据库的473124人数据,纳入两次血清尿酸超过6.8 mg/dL的301385例高尿酸血症成人,按第二次尿酸水平四分位分组,评估痛风诊断发生率。最高四分位者10年内13%发生痛风,年发生率稳定在1.3%,血清尿酸水平是与痛风发生率显著增加相关的最重要危险因素。
要点
- 301385例高尿酸血症者中15055例(5%)在索引日期后诊断为痛风。
- 最高尿酸四分位者10年内13%发生痛风,年发生率稳定在1.3%。
- 最高尿酸四分位者无痛风生存率呈最陡的线性下降(log-rank检验P值<0.0001)。
核心结论
- 在高尿酸血症参与者中,血清尿酸水平是与痛风发生率显著增加相关的最重要危险因素。
研究设计与样本
- 回顾性全国性以色列队列研究,使用Clalit健康保险数据库473124人数据,纳入2007年1月至2022年12月间至少两次血清尿酸测量超过6.8 mg/dL的16岁及以上成人,排除既往痛风诊断或使用痛风药物者。
- 主要结局为第二次高尿酸血症记录后至少90天诊断痛风,按第二次血清尿酸水平分为四个四分位,采用Cox比例风险回归进行生存分析。
主要发现
- 301385例被定义为高尿酸血症,其中15055例(5%)在索引日期后诊断为痛风。
- 各四分位第二次血清尿酸均值/中位数分别为6.95/6.96 mg/dL、7.20/7.20 mg/dL、7.58/7.60 mg/dL和8.62/8.38 mg/dL。
- 最高血清尿酸四分位者无痛风生存率呈最陡的线性下降(log-rank检验P值<0.0001)。
- 最高四分位者10年内13%发生痛风,该四分位年痛风发生率稳定在1.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the relationship between serum urate (SU) levels in hyperuricemic participants and the risk of developing gout. METHODS: A retrospective nationwide Israeli cohort study used the Clalit Health Insurance database of 473,124 individuals to identify adults aged 16 or older with at least two SU measurements exceeding 6.8 mg/dL between January 2007 and December 2022. Participants with a prior gout diagnosis or on gout medications were excluded. The primary outcome was a gout diagnosis, at least 90 days after the second record of hyperuricemia. Individuals were divided into four quartiles according to their second SU level. Survival analysis using Cox proportional hazards regression was conducted to evaluate the incidence of gout across SU quartiles. RESULTS: 301,385 participants were defined as having hyperuricemia, of whom 15,055 (5 %) were diagnosed with gout after the index date. The mean/median of the second SU level of each quartile was 6.95/6.96 mg/dL, 7.20/7.20 mg/dL, 7.58/7.60 mg/dL, and 8.62/8.38 mg/dL, respectively. Participants with hyperuricemia from the highest SU quartile showed the steepest linear decline rate of gout-free survival (log-rank test P-value<0.0001). Thirteen percent (13 %) of participants in the highest SU quartile developed gout over 10 years, also showing a steady annual incidence rate of gout of 1.3 % (in that fourth quartile). CONCLUSION: Among participants with hyperuricemia, SU level stands out as the most important risk factor associated with significant increase in the incidence of gout.
引用
- Brikman S, Perets O, Serfaty L, et al. Incidence of gout diagnosis among participants with hyperuricemia, insights from a nationwide cohort study. Semin Arthritis Rheum. 2025. PMID: 40570634. doi:10.1016/j.semarthrit.2025.152764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。